Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HR19042
- Development stage
- Phase 2
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HR19042 is an oral small molecule drug under development by Jiangsu Hengrui Medicine for the treatment of primary IgA nephropathy and autoimmune hepatitis. It is classified as an anti-inflammatory and urologic agent, though its precise mechanism of action has not been defined. The drug is a new molecular entity and has reached Phase II clinical trials in both autoimmune hepatitis and IgA nephropathy in China. For autoimmune hepatitis, it has been recognized as a breakthrough therapy variety by the Drug Evaluation Center in China due to its selective anti-inflammatory effects on the liver. There are currently no similar approved products for this indication in China.
Beyond the preview
Go deeper on HR19042.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HR19042.